Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
posted
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
TiGenix (NYSE Euronext: TIG), a leading biopharmaceutical company that commercializes and develops cell therapies, announced today that as the coordinator of an international consortium it has obtained a substantial grant from the European Seventh Framework Programme (FP7) to support the development of its Cx611 program of allogeneic expanded adipose derived stem cells for the treatment of rheumatoid arthritis. The so-called REGENER-AR consortium includes 10 partners from Spain, France, the UK, the Netherlands and Belgium, and consists of a combination of top-level research institutes, medical entities and biotech companies. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announces that it has submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin Intravitreal Injection, 2.5 mg/mL, for the treatment of symptomatic VMA including macular hole. read more
VIB has submitted an application for a field experiment with genetically modified maize. The maize becomes taller than conventional maize – at least in a greenhouse. The field experiment is to show whether or not the maize also becomes taller under normal agricultural conditions and whether the plants are suited to be planted closer together. This could contribute to a higher yield. The permit is requested for three seasons, starting in 2012. The field experiment will be carried out in Wetteren on grounds of the Agriculture and Fisheries Research Institute (ILVO), a scientific institution of the Flemish government. read more
Panama Green Fuels, a company with ambitions to develop green fuel projects in Panama in close collaboration with the Panama government, has agreed to become a member of the Jatropha curcas knowledge platforms of QUINVITA. Both parties maintained an option to develop their relationship for Panama based development of Jatropha plantations on a mutually exclusive basis. read more
Galapagos NV (Euronext: GLPG) announced today that it has initiated clinical Phase I development of the first inhibitor of GPR43, a novel target for inflammatory diseases. This target was identified through Galapagos' proprietary target discovery platform. read more
TiGenix (NYSE Euronext: TIG) announced today that it has obtained all the required approvals to start the company's Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621). The Phase I will enroll 10 healthy volunteers and the company expects the last volunteer to be dosed in April, with final results reported by June 2012. Cx621 aims to capitalize on the benefits of TiGenix's proprietary approach of intra-lymphatic administration to treat autoimmune disorders. read more
Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises. read more
Despite advanced genome technologies, it remains a major challenge to identify small variations between the hereditary material (DNA) of different individuals with certainty. VIB scientists connected to the K. U. Leuven and the University of Antwerp describe in Nature Biotechnology a method that makes it possible to trace genetic variations in the DNA with a high degree of certainty. read more
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody™ platform, announced today it has received a grant of €1.3 million to further advance its powerful discovery platform for addressing challenging disease targets. The grant was awarded by the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), and is the third award the Company has received from the institute, totalling €4.1 million to date. read more
